relative risk of death (a ¼ 0.05). We also explored other maximum ferritin level thresholds (41500, 42000, 42500 ng/ml) without reaching a significant association. The IPSS score was the only independent variable in this subset of patients (HR 1.6 (1.2-2.1, 95% CI), Pp0.001).
In a sample of 176 MDS patients, treated only with supportive care, multivariate Cox regression analysis showed that the IPSS was the only independent prognostic variable on survival, among another six clinical and laboratory variables. In addition, ferritin levels failed to show an independent impact on survival either after multivariate adjustment or after transfusion requirement cohort stratification.
The IPSS score remained a valuable prognostic tool in our series, even after adjusting for some prognostic factors that were not considered when it was designed. 4 Contrary to other proposed scores, IPSS variables were already present at diagnosis, making therapeutic planning and patient counseling accurate at baseline. The latter, together with the IPSS validation in numerous studies (including ours), further supports its priority use in MDS patient management and clinical trials. This is a negative study, as our main hypothesis (that high ferritin levels independently worsen survival in MDS patients) has not been validated. However, we consider that our work has a crucial lesson: not adjusting for transfusion requirement or disease aggressiveness may lead to an incorrect association. Susceptibility bias occurs when groups of patients assembled for a study differ in ways other than the factor in question. These extraneous factors, not the particular factors being analyzed, may determine the outcome. 5 Biases that produce confusion require the concurrence of two phenomena: a particular effectmodifying factor that alters the outcome of the event and a substantially unequal distribution in subgroups among the cohort. 6 Dysplasia is heterogeneously distributed through the MDS spectrum and its intensity clearly affects transfusion requirement, and consequently, iron overload.
We acknowledge that there are several limitations to our study. First, this is a retrospective study and serum ferritin levels were not routinely determined through follow-up. It explains the exclusion of 23 patients owing to ferritin missing data, most of them (95%) before 2003, reflecting the emerging concerns about iron overload in the last years in the MDS field. Second, serum ferritin has the properties of an acute-phase reactant, and this fact may represent a measurement bias. We attempted to minimize the concerns about this effect by not considering serum ferritin levels determined in the context of processes or surgical procedures that needed hospital admission. Finally, the exclusion of 11 patients who received iron-chelation therapy, although obviously needed, may imply a selection bias itself. However, it is our opinion that the exclusion of those 11 patients does not distort our conclusions as the median time from diagnosis to the beginning of chelation therapy was scarcely inferior (median 31 months, IQR 19-46 months) to the whole cohort's median survival time (median 39 months, IQR 17-79 months).
MDSs include entities with different clinical course and biological basis, in which planned precautions to avoid confounding (prospective clinical trials) must overcome remedial adjustments in prognostic studies. Genomic and expression analyses of human B-cell precursor acute lymphoblastic leukemia (BCP-ALL) have uncovered several oncogenic events that contribute to the transformation of B-cell progenitors. 1 Besides BCR-ABL1, mutations and rearrangements detected in BCP-ALL predominantly affect genes coding for transcriptional regulators involved in the control of early hematopoietic differentiation, B-cell development or both. Activating mutations in the JAK2 gene that targets the R683 residue [2] [3] [4] have been recently suggested to cooperate with the transcriptional activation of the gene coding for the cytokine receptor chain gene TSLPR/CRLF2.
5 TSLPR codes for a cytokine receptor chain related to gc/IL2Rc. Both chains are able to interact with IL7R to constitute the receptor for IL7 (gc þ IL7R) or TSLP (TSLPR þ IL7R). Signaling from the IL7 receptor is known to involve JAK1 and JAK3 whereas intracellular signaling by the TSLP receptor is poorly characterized. 6 In BCP-ALL, aberrant expression of TSLPR itself occurs through either a cryptic chromosomal translocation between the TSLPR locus (Xp22/ Yp11) and the immunoglobulin heavy-chain locus (14q32) or through a deletion of chromosome X or Y pseudoautosomal sequences juxtaposing the P2RY8 gene to TSLPR.
5 Sox5 upregulation through juxtaposition to the P2RY8 promoter has been previously reported in lymphoma.
Activation of the JAK-STAT pathway through an activating mutation of the JAK2 gene, JAK2V617F, has been described in human myeloproliferative neoplasms (MPN). 8 In a proportion of MPN patients, primitive myelofibrosis and essential thrombocytemia, mutations targeting the W515 residue of MPL, the homodimeric receptor chain for TPO, have been observed. 9 Wild-type (WT) MPL intracellular signaling activates the JAK-STAT pathway through JAK2. The mutant MPL experimentally leads to a constitutive activation of the JAK-STAT pathway. In a subset of patients, MPL mutations are associated to JAK2V617F. This situation presumably represents oncogenic cooperation leading to a stronger JAK-STAT activity than either JAK2 or MPL mutation alone. 9 The parallel situation seen in BCP-ALL and MPN prompted us to investigate whether an activating mutation was present in the TSLPR gene. Indeed, we initially described a mutated form of JAK2 (JAK2dIREED; Malinge et al.
2 ) in a Down's syndrome patient with BCP-ALL. This patient was later shown to express a TSLPR transcript with WT coding sequence (data not shown), further supporting a functional cooperation between TSLPR and JAK2 in lymphoid transformation. We therefore investigated a series of BCP-ALL patients for expression and mutation of the TSLPR and JAK2 genes.
We first examined the transcription of TSLPR and of JAK2 in a series of 60 BCP-ALL patients, using qualitative (data not shown) or quantitative (Figure 1a) RT-PCR. Patients were selected on the basis of available material. The series comprised both children (n ¼ 50) and adults (n ¼ 10). Expression was compared to the MUTZ5 and MHH-CALL-4 leukemic cell lines that have an unbalanced t(Y;14)(p11;q32) translocation and express a mutated JAK2.
5
JAK2 expression was found to be homogeneous between samples. Most of them expressed JAK2 at a level comparable to the references cell lines, with 10% of the samples expressing a low level of JAK2.
Three samples (940, 3928 and 4486; Figure 1 ; Supplementary Table 1 ; data not shown) exhibited elevated expression of TSLPR. Results of fluorescence in situ hybridization analysis confirmed that patient 4486 was having a t(Y;14)(p11;q32) translocation (data not shown), but no material was available to test for the presence of a rearrangement of the TSLPR gene in the remaining two samples.
Next we searched for nucleotide variation that might affect JAK2R683 or TSLPR. The nucleotide sequence of JAK2 exon 14, which includes codon R683, was analyzed using genomic DNA of all 50 children BCP-ALL and found to be WT. The nucleotide sequence of the entire coding region of TSLPR was analyzed from cDNA in the 30 samples that expressed TSLPR and had sufficient material available. Eleven patients were shown to express a splice variant of TSLPR, which results in the loss of Letters to the Editor patient (4486; Figure 1b) . It results in an F-C substitution at amino-acid position 232, occurring close to the cytoplasmic side of the predicted transmembrane helix of the human TSLPR protein (Figure 1c) .
These results indicate that TSLPR activation may occur independently of a JAK2R683 mutation and that TSLPR can also be the site of a point mutation. This point mutation that introduces a cysteine residue at the edge of the transmembrane peptide of TSLPR resembles murine EPOR mutation (R129C) shown to induce constitutive dimerization of the receptor. 10 As TSLP signaling has been shown to be important in mast cell activation, 11 we also investigated the TSLPR nucleotide sequence in bone marrow RNA of 37 patients with mastocytosis (n ¼ 3, cutaneous mastocytosis; n ¼ 26, systemic mastocytosis (SM); n ¼ 5, aggressive SM and n ¼ 3, mast cell leukemia). Although the TSLPRF232C mutation was not observed, recurrent TSLPR nucleotide variations were found in these patients (Supplementary Table 2 ). It was noteworthy that mutations in JAK2 were not identified in these patients whereas 75% of them presented with the expected gain-of-function KIT mutation.
To functionally investigate the TSLPRF232C mutation, we expressed WT TSLPR or mutated TSLPRF232C, in combination with WT or mutated JAK2 from retroviral backbones in the IL3-dependent Ba/F3 cell line, which does not endogenously express TSLPR and IL7R chains. 12, 13 As shown in Figure 2 , TSLPRF232C expression was able to induce IL3-independent growth of Ba/F3 cells whereas WT TSLPR expression was not. In addition, mutant JAK2dIREED cooperated efficiently with the WT TSLPR to induce cytokineindependent survival and growth of Ba/F3 cells. Moreover of expression in TSLPRWT þ JAK2dIREED-expressing cells when compared with TSLPRWT þ JAK2WT cells.
We also expressed TSLPRF232C in primary bone marrow cells using a bone marrow transplantation approach as previously described. 2, 14 Mice engrafted with progenitors transduced with WT TSLPR-expressing retroviruses or with control empty viruses showed no evidence of a hematological disorder after 1 year of follow-up (data not shown). Four out of six mice transplanted with progenitor cells expressing TSLPRF232C exhibited a high percentage of green fluorescent protein (GFP)-expressing cells (49.5%) in the blood and showed signs of myeloproliferation 2 months after transplantation (Hgb 415.5 g per 100 ml, increase in white and red blood cell count; see Supplementary Table 3 ). Detailed examination of one of these mice showed enlargement of the spleen and liver, an increase number of immature granulocytes in the bone marrow and spleen, immature megakaryocytes in bone marrow and immature erythrocytes in the spleen (Supplementary Figure 1) . In vitro myeloid colony-forming ability of bone marrow and spleen cells showed an increased number of erythroid colonies in TSLPRF232C animals compared with controls when cells were grown in the presence of cytokines. Cells taken from both sites were also able to generate 'spontaneous' colonies in vitro, in the absence of cytokines (Supplementary Figure 1) . Unfortunately, GFP þ cells contributed poorly to lymphoid differentiation in this model. It was noted that transduction of bone marrow cells using IL7 stimulation, in place of IL3, IL6 and stem cell factor, to favor lymphoid progenitors transduction resulted in a higher contribution of the GFP þ cells to the B220 þ CD19 þ population without production of lymphoid malignancies at more than 1 year of follow-up (data not shown).
Taken together, these results indicate that the TSLPRF232C is able to induce a myeloproliferative-like syndrome in a bone marrow transplant mouse model, indicating that it constitutes a bona fide activated allele. Further modeling to specifically express the WT and mutant TSLPR forms in lymphoid progenitors is required to understand their role during BCP-ALL transformation.
